

# Georgios Giamas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4510460/publications.pdf>

Version: 2024-02-01

93  
papers

2,794  
citations

186265  
28  
h-index

189892  
50  
g-index

96  
all docs

96  
docs citations

96  
times ranked

5133  
citing authors

#	ARTICLE	IF	CITATIONS
1	The estrogen receptor- $\alpha$ -induced microRNA signature regulates itself and its transcriptional response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15732-15737.	7.1	306
2	Endocrine Resistance in Hormone Receptor Positive Breast Cancer—From Mechanism to Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 245.	3.5	150
3	MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors. <i>PLoS ONE</i> , 2012, 7, e32068.	2.5	122
4	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. <i>Nature Medicine</i> , 2011, 17, 715-719.	30.7	118
5	Extracellular vesicles swarm the cancer microenvironment: from tumor—stroma communication to drug intervention. <i>Oncogene</i> , 2017, 36, 877-884.	5.9	117
6	Astrocytes, the rising stars of the glioblastoma microenvironment. <i>Glia</i> , 2019, 67, 779-790.	4.9	115
7	Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 <i>in vitro</i> and <i>in vivo</i> . <i>Gut</i> , 2008, 57, 799-806.	12.1	91
8	The regulatory roles of phosphatases in cancer. <i>Oncogene</i> , 2014, 33, 939-953.	5.9	89
9	Kinases as targets in the treatment of solid tumors. <i>Cellular Signalling</i> , 2010, 22, 984-1002.	3.6	88
10	The Role of the Casein Kinase 1 (CK1) Family in Different Signaling Pathways Linked to Cancer Development. <i>Oncology Research and Treatment</i> , 2005, 28, 508-514.	1.2	86
11	Breaking through the glioblastoma micro-environment via extracellular vesicles. <i>Oncogene</i> , 2020, 39, 4477-4490.	5.9	72
12	Nicestrin regulates breast cancer stem cell properties and tumor growth <i>in vitro</i> and <i>in vivo</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16558-16563.	7.1	71
13	Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. <i>Communications Biology</i> , 2019, 2, 315.	4.4	71
14	Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. <i>Trends in Molecular Medicine</i> , 2017, 23, 282-292.	6.7	70
15	Protein kinases as targets for cancer treatment. <i>Pharmacogenomics</i> , 2007, 8, 1005-1016.	1.3	68
16	Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. <i>Molecular Cancer</i> , 2018, 17, 132.	19.2	67
17	Phosphorylation of CK1 $\delta$ : identification of Ser370 as the major phosphorylation site targeted by PKA <i>in vitro</i> and <i>in vivo</i> . <i>Biochemical Journal</i> , 2007, 406, 389-398.	3.7	64
18	Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. <i>Frontiers in Endocrinology</i> , 2019, 10, 682.	3.5	52

#	ARTICLE	IF	CITATIONS
19	Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. <i>EMBO Journal</i> , 2007, 26, 4619-4633.	7.8	47
20	Claudin-1 as a promoter of EMT in hepatocellular carcinoma. <i>Oncogene</i> , 2013, 32, 4871-4872.	5.9	44
21	LMTK3 is implicated in endocrine resistance via multiple signaling pathways. <i>Oncogene</i> , 2013, 32, 3371-3380.	5.9	40
22	A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers. <i>Frontiers in Immunology</i> , 2021, 12, 762598.	4.8	39
23	The dual function of KSR1: a pseudokinase and beyond. <i>Biochemical Society Transactions</i> , 2013, 41, 1078-1082.	3.4	37
24	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 537-544.	2.5	35
25	PIK3CÎ expression by fibroblasts promotes triple-negative breast cancer progression. <i>Journal of Clinical Investigation</i> , 2020, 130, 3188-3204.	8.2	33
26	The role of pseudokinases in cancer. <i>Cellular Signalling</i> , 2012, 24, 1173-1184.	3.6	32
27	The Kinase LMTK3 Promotes Invasion in Breast Cancer Through GRB2-Mediated Induction of Integrin Î²<sub>1</sub>. <i>Science Signaling</i> , 2014, 7, ra58.	3.6	32
28	LMTK3 confers chemo-resistance in breast cancer. <i>Oncogene</i> , 2018, 37, 3113-3130.	5.9	31
29	LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. <i>Cancer Letters</i> , 2016, 372, 137-146.	7.2	30
30	Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen. <i>Pharmacogenomics Journal</i> , 2014, 14, 28-34.	2.0	29
31	Tumorâ€™Stromal Cell Communication: Small Vesicles Signal Big Changes. <i>Trends in Cancer</i> , 2016, 2, 326-329.	7.4	28
32	Casein kinase 1 delta (CK1Î´) interacts with the SNARE associated protein snapin. <i>FEBS Letters</i> , 2006, 580, 6477-6484.	2.8	27
33	CK1Î´ modulates the transcriptional activity of ERÎ± via AIB1 in an estrogen-dependent manner and regulates ERÎ±â€™AIB1 interactions. <i>Nucleic Acids Research</i> , 2009, 37, 3110-3123.	14.5	27
34	MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma. <i>PLoS ONE</i> , 2014, 9, e85935.	2.5	26
35	Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing. <i>Oncogene</i> , 2020, 39, 6172-6189.	5.9	23
36	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. <i>Cell Reports</i> , 2015, 12, 837-849.	6.4	21

#	ARTICLE	IF	CITATIONS
37	ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. <i>Oncotarget</i> , 2016, 7, 27599-27612.	1.8	21
38	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2261-2272.	4.1	19
39	Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	19
40	LATS2 is a modulator of estrogen receptor alpha. <i>Anticancer Research</i> , 2013, 33, 53-63.	1.1	19
41	When does a human being die?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 605-609.	0.5	18
42	The structure-function relationship of oncogenic LMTK3. <i>Science Advances</i> , 2020, 6, .	10.3	18
43	Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 2479-2492.	3.8	17
44	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. <i>Oncogene</i> , 2015, 34, 2103-2114.	5.9	17
45	SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1. <i>British Journal of Cancer</i> , 2013, 109, 2675-2684.	6.4	16
46	The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 165372.	3.8	15
47	The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. <i>Cancer</i> , 2008, 113, 1489-1495.	4.1	14
48	PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling. <i>Oncogene</i> , 2022, 41, 2749-2763.	5.9	14
49	Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth. <i>Hepatology</i> , 2021, 74, 2561-2579.	7.3	13
50	Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution. <i>Oncotarget</i> , 2011, 2, 428-429.	1.8	12
51	Three Method-Combination Protocol for Improving Purity of Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3071.	4.1	11
52	Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 555-568.	2.5	10
53	Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients. <i>Biomedicines</i> , 2022, 10, 125.	3.2	10
54	Graphene-Induced Transdifferentiation of Cancer Stem Cells as a Therapeutic Strategy against Glioblastoma. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 3258-3269.	5.2	9

#	ARTICLE	IF	CITATIONS
55	The role of astrocytes in brain metastasis at the interface of circulating tumour cells and the blood brain barrier. <i>Frontiers in Bioscience</i> , 2021, 26, 590.	2.1	9
56	Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12015.	4.1	9
57	Bendamustine as a model for the activity of alkylating agents. <i>Future Oncology</i> , 2008, 4, 323-332.	2.4	7
58	Strategies in functional proteomics: Unveiling the pathways to precision oncology. <i>Cancer Letters</i> , 2016, 382, 86-94.	7.2	7
59	Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor. <i>Oncogene</i> , 2016, 35, 2562-2564.	5.9	7
60	Cancer Gene Therapy: vision and strategy for the new decade. <i>Cancer Gene Therapy</i> , 2020, 27, 115-115.	4.6	7
61	Extracellular Vesicles as Mediators of Therapy Resistance in the Breast Cancer Microenvironment. <i>Biomolecules</i> , 2022, 12, 132.	4.0	7
62	LMTK3 inhibition affects microtubule stability. <i>Molecular Cancer</i> , 2021, 20, 53.	19.2	6
63	LMTK3 polymorphism in patients with metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 471-471.	1.6	6
64	EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR?. <i>Endocrine Connections</i> , 2019, 8, 680-690.	1.9	6
65	Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer. <i>Expert Review of Proteomics</i> , 2014, 11, 713-731.	3.0	5
66	Cancer gene therapy 2020: highlights from a challenging year. <i>Cancer Gene Therapy</i> , 2022, 29, 1-3.	4.6	4
67	The multifaceted role of lemur tyrosine kinase 3 in health and disease. <i>Open Biology</i> , 2021, 11, 210218.	3.6	4
68	Targeting lemurs against cancer metastasis. <i>Oncotarget</i> , 2014, 5, 5192-5193.	1.8	4
69	Tunable synthetic reduced graphene oxide scaffolds elicit high levels of three-dimensional glioblastoma interconnectivity <i>in vitro</i> . <i>Journal of Materials Chemistry B</i> , 2022, 10, 373-383.	5.8	4
70	Cancer stem cells—therapeutic targeting or therapy?. <i>Lancet Oncology</i> , The, 2013, 14, 579-580.	10.7	3
71	Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer. <i>Data in Brief</i> , 2016, 7, 740-746.	1.0	3
72	miRNA transported by exosomes: a key machinery in tumor microenvironment mediated chemoresistance. <i>Translational Cancer Research</i> , 2016, 5, S1479-S1482.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Association of gender-related tumor recurrence with a polymorphic variant of LMTK3 in stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 454-454.	1.6	3
74	Diving into the dark kinome: lessons learned from LMTK3. <i>Cancer Gene Therapy</i> , 2022, 29, 1077-1079.	4.6	3
75	Clinical significance of circulating tumor cells. <i>Biomarkers in Medicine</i> , 2007, 1, 341-342.	1.4	2
76	The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy. <i>Annals of Oncology</i> , 2011, 22, 1700-1702.	1.2	2
77	Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER±-positive advanced breast cancer. <i>Pharmacogenomics Journal</i> , 2015, 15, 235-240.	2.0	2
78	Advances in integrative statistics for logic programming. <i>International Journal of Approximate Reasoning</i> , 2016, 78, 103-115.	3.3	2
79	Langmuir Films of Layered Nanomaterials: Edge Interactions and Cell Culture Applications. <i>Journal of Physical Chemistry B</i> , 2020, 124, 7184-7193.	2.6	2
80	Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas. <i>Cancer Gene Therapy</i> , 2022, 29, 1418-1428.	4.6	2
81	A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 778637.	2.8	2
82	Use of genetic variants of LMTK3 to predict tumor recurrence in female localized gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 63-63.	1.6	1
83	Breast cancer and LMTK3: old disease, new target. <i>Breast Cancer Management</i> , 2012, 1, 101-103.	0.2	0
84	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management. <i>Breast Cancer Management</i> , 2013, 2, 455-457.	0.2	0
85	mTOR inhibition in breast cancer. <i>Breast Cancer Management</i> , 2015, 4, 67-70.	0.2	0
86	Reply: When does a human being die?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 146-146.	0.5	0
87	Reviewer Recognition. <i>Cancer Gene Therapy</i> , 2020, 27, 264-264.	4.6	0
88	Abstract LB-226: Identification of novel kinases modulating ER: new therapeutic targets in breast cancer. , 2010, , .		0
89	Genetic variants of kinases suppressors of ras in <i>KRAS</i> - <i>BRAF</i> wild-type metastatic colorectal cancer patients treated with cetuximab and irinotecan.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3597-3597.	1.6	0
90	Genetic variants of kinases suppressors of ras (KSR1) to predict survival in patients with ER-alpha positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11018-e11018.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Prognostic value of lemur tyrosine kinase-3 (LMTK3) polymorphism in Japanese (J) patients (PTS) with localized gastric adenocarcinoma (GAC).. Journal of Clinical Oncology, 2012, 30, 4088-4088.	1.6	0
92	KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab.. Journal of Clinical Oncology, 2012, 30, 3546-3546.	1.6	0
93	The many-faced KSR1: a tumor suppressor in breast cancer. Oncoscience, 2015, 2, 669-670.	2.2	0